source
- Akeso reports survival benefit for ivonescimab in China-only biliary tract cancer trial, likening results to KeytrudaAkeso announced new data from a late‑stage study of its PD‑1×VEGF bispecific antibody ivonescimab in patients with biliary tract cancer enrolled only in China. The trial showed an improvement in o…
- AstraZeneca, Lilly and Bayer unveil new strategies at ESMO 2026 in MadridAt the European Society for Medical Oncology (ESMO) congress in Madrid, nearly 40,000 delegates gathered for the five-day meeting. AstraZeneca said it is evaluating the use of its immunotherapy Ke…